Resalis Therapeutics
Biopharma company focused on the development of oligonucleotide anti-sense therapies to treat metabolic disorders, including NAFLD/MAFLD/NASH, obesity, and cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | Early VC | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 2700 % | 116127 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (117492350 %) | (122369650 %) | (5591020 %) | (8207 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Resalis Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of treatments for metabolic diseases such as obesity and fatty liver disease. The company's innovative approach targets a master regulator of multiple pathways that underlie these diseases, using a non-coding RNA drug modality. In simpler terms, they are developing drugs that can interact with our genetic material to regulate the body's metabolism and combat these diseases.
Their lead program, RES-010, is being developed as a safe and convenient treatment that not only aids in weight loss but also reduces hepatic steatosis, a condition characterized by the buildup of fat in the liver. The company's business model revolves around the research, development, and eventual commercialization of this drug. They aim to generate revenue through the sale of RES-010 once it has been approved for use in the market.
Resalis Therapeutics serves a broad client base that includes individuals suffering from obesity and fatty liver disease. Given the increasing prevalence of these conditions globally, the market potential for their product is significant. The company is currently in the preclinical stage, gathering robust evidence to support the effectiveness of RES-010. They plan to rapidly progress to clinical trials, testing the drug on a range of metabolic disorders.
Keywords: Biotechnology, Healthcare, Metabolic Diseases, Obesity, Fatty Liver Disease, Non-Coding RNA Drug Modality, RES-010, Drug Development, Clinical Trials, Hepatic Steatosis.